Drugs / MER511
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07305818 | Dec 2025 → Jul 2028 expected | Graves disease | Merida Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-31 | Eli Lilly and Company | Results Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases lilly.com ↗
Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-31 | Eli Lilly and Company | Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases lilly.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MER511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07305818 ↗ |
| Route | Intravenous | “via IV administration” NCT07305818 ↗ |